Our Company
Transparency Information
At Alnylam, we strongly believe that interactions with Health Care Professionals (HCPs) and Healthcare Organisations (HCOs) positively influence the quality of patient treatment and the value of medical research. We’re also fully committed to increased transparency within the pharmaceutical industry and to strengthening the public trust in the relationships between pharmaceutical companies and HCPs and HCOs.
We believe healthcare professionals, other relevant decision makers, and healthcare organisations should be fairly compensated for the legitimate expertise and services they provide. Alnylam voluntarily discloses Transfers of Value to HCPs and HCOs in accordance with the Association of the British Pharmaceutical Industry (ABPI) Code of Practice and/or local legal requirements, and in accordance with all applicable data protection laws and regulations.
For access to reports and methodological notes related to UK data publication in compliance with the ABPI Code of Practice and other applicable local codes, click here.
ALNYLAM IN THE UK
UK Disclosure Reports are available on the ABPI Disclosure UK website.
The UK Transparency Reporting Methodological Note can be viewed here.
For more information on transparency beyond the UK, you can visit our global transparency page, here.